Glaxo turning point won’t be this year, says Liberum5 Feb 2021 05:13
The guidance for this year delivered by GlaxoSmithKline (GSK), including the prospect of a dividend cut, will stifle its share price impetus in the near-term, but Liberum is still expecting the pharmaceutical giant to recover strongly down the line.
Analyst Alistair Campbell retained his ‘buy’ recommendation but reduced the target price from £17.20 to £17.00 on the stock, which closed up 0.2%, or 3p, at £12.85 on Thursday.
He said a 2021 guidance update ‘didn’t mark the turning point we had hoped for and will mark another year of falling earnings’, but that headwinds should be ‘transient’ with the firm’s vaccines division likely to recover in 2022.
‘Furthermore, we saw encouraging signs in the recent performance of the respiratory, HIV, and oncology franchises that reinforce our confidence in the medium-term growth scenario,’ said Campbell.
‘The recovery may be delayed a year but will likely show a sharper bounce.’